PDRadiopharma’s mission, together with PeptiDream, is discovering the next generation of transformational medicines. Our vision is we aim to brighten patients’ lives through the realization of innovative diagnostic and therapeutic radiopharmaceuticals.

Since its establishment in 1968 as a forerunner in the field of radiopharmaceuticals, PDRadiopharma has been manufacturing and providing high-quality diagnostics and therapeutics for patients suffering from brain, heart, and bone diseases, as well as cancer.
After joining the PeptiDream Group in 2022, we have taken on a new challenge to create and develop “theranostic” radiopharmaceuticals utilizing targeted peptides, an innovative modality, enabling treatment and diagnosis to be carried out with the same ligand, by combining PeptiDream’s world-leading peptide drug discovery technology with our research and development capabilities. We believe that this synergy with PeptiDream will significantly benefit cancer patients with high unmet medical needs.
Our patient-first approach, passion for developing new products by using cutting-edge technology and science, and commitment to stable supply of our products are key principles of our company throughout its history, and we will continue this legacy by providing radiotherapeutics as a novel treatment option for patients with our greatest efforts.
PDRadiopharma will continue to maximize our corporate resources, strengthen the governance, and foster a culture of respect, empowerment and diversity among its employees with the objective to be a trusted company for patients, their family and health care providers and to contribute to the sustainable future of our society.

PDRadiopharma Inc.

Org chart

Teams

Offices